Martin Ccorisapra Roman

2 records, newest first. Each line links to the FDA page it came from.

Refusal charges, in plain English

• UNAPPROVED1 refused line

  Unapproved new drug

  The product appeared to be a new drug within the meaning of section 201(p) of the FD&C Act without an approved New Drug Application. FDA can apply this charge to a food or supplement whose labeling presents it for drug uses.

Questions about Martin Ccorisapra Roman

Is Martin Ccorisapra Roman on an FDA import alert?

No listing for Martin Ccorisapra Roman appears in the FDA import alerts SupplierRadar checked on October 26, 2026. Country-wide alerts may still apply to its products; see the Peru page.

Has FDA refused shipments from Martin Ccorisapra Roman?

Yes. FDA refused 1 shipment line from Martin Ccorisapra Roman on July 17, 2025. The most recent, on July 17, 2025, was herbals & botanicals (not teas), n.e.c., charged as UNAPPROVED (unapproved new drug).

Why did FDA refuse Martin Ccorisapra Roman's shipments?

The most frequent charge is UNAPPROVED (unapproved new drug, 1 line).

When was Martin Ccorisapra Roman last inspected by FDA?

FDA's most recent inspection of Martin Ccorisapra Roman with a final classification is dated April 17, 2018 and was classified VAI (Voluntary Action Indicated).

What is Martin Ccorisapra Roman's FEI number?

Martin Ccorisapra Roman's FDA Establishment Identifier (FEI) is 3005109660.